THE LONG DAWN

Dispatches / Cancer

The long siege of cancer

FDA grants accelerated approval to neladalkib for ALK-positive lung cancer after earlier therapy

Each generation of targeted drug reaches further down the same road.

ApprovedRegulator decision

What happened

  • On 17 Nov 2026 the FDA granted accelerated approval to neladalkib (Nelkarmi, Nuvalent) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer.
  • It is for people previously treated with alectinib, or with two or more ALK inhibitors plus platinum chemotherapy.

What we don't know yet

  • Accelerated approval means confirmatory trials must still show clinical benefit.
  • The FDA notice we read gives the indication; trial numbers are in the label, not summarised here yet.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.